SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-037773
Filing Date
2021-07-20
Accepted
2021-07-20 17:10:09
Documents
4
Period of Report
2021-07-20

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea144517-6k_regencellbio.htm 6-K 17771
2 UNDERWRITING AGREEMENT, DATED AS OF JULY 15, 2021, BY AND BETWEEN REGENCELL BIOS ea144517ex1-1_regencell.htm EX-1.1 383883
3 PRESS RELEASE ON PRICING OF THE COMPANY'S INITIAL PUBLIC OFFERING ea144517ex99-1_regencell.htm EX-99.1 16478
4 PRESS RELEASE ON CLOSING OF THE COMPANY'S INITIAL PUBLIC OFFERING ea144517ex99-2_regencell.htm EX-99.2 15956
  Complete submission text file 0001213900-21-037773.txt   435177
Mailing Address 11/F FIRST COMMERCIAL BUILDING 33-35 LEIGHTON ROAD, CAUSEWAY BAY HONG KONG K3 999077
Business Address 11/F FIRST COMMERCIAL BUILDING 33-35 LEIGHTON ROAD, CAUSEWAY BAY HONG KONG K3 999077 852 2155 0823
Regencell Bioscience Holdings Ltd (Filer) CIK: 0001829667 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9
Type: 6-K | Act: 34 | File No.: 001-40617 | Film No.: 211101868
SIC: 2833 Medicinal Chemicals & Botanical Products